Diagnostic criteria for amyotrophic lateral sclerosis

Area of Science:

• Neurology
• Clinical Diagnostics

Background:

• Amyotrophic lateral sclerosis (ALS) diagnosis relies on specific clinical criteria.
• Existing criteria like the revised El Escorial (rEEC) and Awaji criteria (AC) have limitations, particularly for atypical presentations.
• There is a need for improved diagnostic sensitivity and broader patient eligibility for clinical trials.

Purpose of the Study:

• To review the evolution of diagnostic criteria for amyotrophic lateral sclerosis (ALS).
• To discuss the development and utility of the Gold Coast consensus criteria (GCC).
• To consider the role of biomarkers in future ALS diagnostics.

Main Methods:

• Review of existing literature and consensus development for diagnostic criteria.
• Comparison of the sensitivity and utility of the Gold Coast consensus criteria (GCC) against previous criteria (rEEC, AC).
• Assessment of the potential impact of GCC on clinical trial enrollment.

Main Results:

• The Gold Coast consensus criteria (GCC) demonstrate similar or greater sensitivity compared to rEEC and AC, especially for atypical ALS phenotypes.
• GCC maintain diagnostic sensitivity across varying disease duration, severity, and onset site.
• Implementing GCC could increase ALS patient enrollment in clinical trials by up to 50%.

Conclusions:

• The GCC offer a simpler and more sensitive approach to diagnosing ALS, enabling earlier and more definitive diagnoses.
• Wider implementation of GCC in clinical trials is ongoing globally.
• Future validation of genetic biomarkers may further refine ALS diagnostic criteria and utility.